DARPA's Potential Treatment for COVID-19

Stop Gap Covid-19 Treatment

Source:  DARPA


Race to Stop COVID-19 in its Tracks
The US Defense Department's Advanced
Research Projects Agency - DARPA -
has been given the green light to
fast track "mission critical" programs
to fight and defeat the coronavirus, 
which has infected nearly 1 million
Americans.  DARPA is a global
epicenter of breakthrough innovation.
It has created the internet, Artificial
Intelligence, cloud computing and 
much more.

Unique Stop Gap Therapy in the Pipeline
Right now, DARPA is working on a
therapy - what they're calling a
"firewall" - that would temporarily 
protect someone from contracting the
disease.  It is a stop-gap therapy
for use before a vaccine is created,
which is expected sometime in 2021 at
the earliest.

Firewall P3 Platform
DARPA wants their P3 Platform therapy 
to work immediately in the patient and last
for six months.  DARPA has identified
antibodies in people who overcame the
disease and they're turning that into 
the stop-gap therapy. They're taking the
genetic materials that code for those
antibodies and injecting them into
patients so their cells can make the 
antibodies. The procedure has already
been successful in limited human
trials.

Targeting Availability in 60 Days
DARPA's stop-gap therapy is
new, cutting edge, experimental
and real.  DARPA's track-record
of record-breaking global innovations
is unparalleled. It could be a light
at the end of the pandemic tunnel.
DARPA hopes to make
this potentially life saving therapy
available in 60 to 90 days.

Comments

Popular posts from this blog

Boxing Robots: Italy's Fast Growth Industry

Important Innovations Collection: Breakthrough on CTE Brain Injuries from Sports

Slowing Down Time to Save Lives